Kalvista Pharmaceuticals position history
The shares of Kalvista Pharmaceuticals that DAFNA Capital Management LLC reported in each quarter’s 13F.
Shares held by quarter
New Add Reduce Exit
- 2021 Q3: 189,163 shares, $3.3M, 0.88% of portfolio
- 2021 Q4: 190,663 shares, $2.5M, 0.63% of portfolio, Add +0.8%
- 2022 Q1: 190,663 shares, $2.8M, 0.73% of portfolio
- 2022 Q2: 265,663 shares, $2.6M, 0.71% of portfolio, Add +39.3%
- 2022 Q3: 255,313 shares, $3.7M, 1.00% of portfolio, Reduce −3.9%
- 2022 Q4: 616,032 shares, $4.2M, 1.2% of portfolio, Add +141.3%
- 2023 Q1: 616,032 shares, $4.8M, 1.5% of portfolio
- 2023 Q2: 611,032 shares, $5.5M, 1.5% of portfolio, Reduce −0.8%
- 2023 Q3: 605,532 shares, $5.8M, 1.8% of portfolio, Reduce −0.9%
- 2023 Q4: 601,032 shares, $7.4M, 1.8% of portfolio, Reduce −0.7%
- 2024 Q1: 806,973 shares, $9.6M, 2.2% of portfolio, Add +34.3%
- 2024 Q2: 806,973 shares, $9.5M, 2.3% of portfolio
- 2024 Q3: 723,678 shares, $8.4M, 2.0% of portfolio, Reduce −10.3%
- 2024 Q4: 811,678 shares, $6.9M, 1.7% of portfolio, Add +12.2%
- 2025 Q1: 752,359 shares, $8.7M, 2.5% of portfolio, Reduce −7.3%
- 2025 Q2: 581,757 shares, $6.6M, 1.8% of portfolio, Reduce −22.7%
- 2025 Q3: 422,731 shares, $5.1M, 1.3% of portfolio, Reduce −27.3%
- 2025 Q4: 356,802 shares, $5.8M, 1.3% of portfolio, Reduce −15.6%
- 2026 Q1: 267,402 shares, $5.4M, 1.2% of portfolio, Reduce −25.1%
- 2026 Q2: not held, Exit
| Holdings date | Value | % of holdings | Shares | Filing date | All 13F holders |
|---|